212 related articles for article (PubMed ID: 18545685)
1. Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice.
Miguel DC; Yokoyama-Yasunaka JK; Uliana SR
PLoS Negl Trop Dis; 2008 Jun; 2(6):e249. PubMed ID: 18545685
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases.
Al-Abdely HM; Graybill JR; Loebenberg D; Melby PC
Antimicrob Agents Chemother; 1999 Dec; 43(12):2910-4. PubMed ID: 10582881
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.
Trinconi CT; Reimão JQ; Coelho AC; Uliana SR
J Antimicrob Chemother; 2016 May; 71(5):1314-22. PubMed ID: 26851606
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B resistance in Leishmania amazonensis: In vitro and in vivo characterization of a Brazilian clinical isolate.
Ferreira BA; Coser EM; de la Roca S; Aoki JI; Branco N; Soares GHC; Lima MIS; Coelho AC
PLoS Negl Trop Dis; 2024 May; 18(5):e0012175. PubMed ID: 38768213
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.
Coelho AC; Trinconi CT; Costa CH; Uliana SR
PLoS Negl Trop Dis; 2014 Jul; 8(7):e2999. PubMed ID: 25033218
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis-infected BALB/c mice reduce parasite load.
da Fonseca-Martins AM; Ramos TD; Pratti JES; Firmino-Cruz L; Gomes DCO; Soong L; Saraiva EM; de Matos Guedes HL
Sci Rep; 2019 Dec; 9(1):20275. PubMed ID: 31889072
[TBL] [Abstract][Full Text] [Related]
9. A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against Leishmania species that cause tegumentary and visceral leishmaniasis.
Sousa JKT; Antinarelli LMR; Mendonça DVC; Lage DP; Tavares GSV; Dias DS; Ribeiro PAF; Ludolf F; Coelho VTS; Oliveira-da-Silva JA; Perin L; Oliveira BA; Alvarenga DF; Chávez-Fumagalli MA; Brandão GC; Nobre V; Pereira GR; Coimbra ES; Coelho EAF
Parasitol Int; 2019 Dec; 73():101966. PubMed ID: 31362122
[TBL] [Abstract][Full Text] [Related]
10. Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different immunoparasitic processes and status of protection in BALB/c mice.
Courret N; Lang T; Milon G; Antoine JC
Int J Parasitol; 2003 Oct; 33(12):1373-83. PubMed ID: 14527520
[TBL] [Abstract][Full Text] [Related]
11. In vivo antileishmanial efficacy of a naphthoquinone derivate incorporated into a Pluronic
Mendonça DVC; Tavares GSV; Lage DP; Soyer TG; Carvalho LM; Dias DS; Ribeiro PAF; Ottoni FM; Antinarelli LMR; Vale DL; Ludolf F; Duarte MC; Coimbra ES; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Barichello JM; Alves RJ; Coelho EAF
Biomed Pharmacother; 2019 Jan; 109():779-787. PubMed ID: 30551531
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
13. Leishmania is not prone to develop resistance to tamoxifen.
Coelho AC; Trinconi CT; Senra L; Yokoyama-Yasunaka JK; Uliana SR
Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):77-83. PubMed ID: 26150922
[TBL] [Abstract][Full Text] [Related]
14. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
[TBL] [Abstract][Full Text] [Related]
15. A standardized intraperitoneal Glucantime™ for experimental treatment of cutaneous leishmaniasis caused by Leishmania amazonensis in BALB/c mice.
Brustolin AÁ; Franzói NM; Ramos-Milaré ÁCFH; Tanoshi CA; Mota CA; Demarchi IG; Lonardoni MVC; Verzignassi Silveira TG
Exp Parasitol; 2022; 236-237():108259. PubMed ID: 35427563
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy induced by the oral administration of Agaricus blazei Murill against Leishmania amazonensis.
Valadares DG; Duarte MC; Ramírez L; Chávez-Fumagalli MA; Lage PS; Martins VT; Costa LE; Ribeiro TG; Régis WC; Soto M; Fernandes AP; Tavares CA; Coelho EA
Parasitol Res; 2012 Oct; 111(4):1807-16. PubMed ID: 22797606
[TBL] [Abstract][Full Text] [Related]
17. Topical tamoxifen in the therapy of cutaneous leishmaniasis.
Trinconi CT; Reimão JQ; Bonano VI; Espada CR; Miguel DC; Yokoyama-Yasunaka JKU; Uliana SRB
Parasitology; 2018 Apr; 145(4):490-496. PubMed ID: 28274283
[TBL] [Abstract][Full Text] [Related]
18. Activity, toxicity and analysis of resistance of essential oil from Chenopodium ambrosioides after intraperitoneal, oral and intralesional administration in BALB/c mice infected with Leishmania amazonensis: a preliminary study.
Monzote L; Montalvo AM; Scull R; Miranda M; Abreu J
Biomed Pharmacother; 2007; 61(2-3):148-53. PubMed ID: 17254746
[TBL] [Abstract][Full Text] [Related]
19. An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis.
Lage LM; Barichello JM; Lage DP; Mendonça DV; Carvalho AM; Rodrigues MR; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Coelho EA; Duarte MC
Parasitol Res; 2016 Nov; 115(11):4083-4095. PubMed ID: 27365053
[TBL] [Abstract][Full Text] [Related]
20. The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis.
Gonçalves-Oliveira LF; Souza-Silva F; de Castro Côrtes LM; Veloso LB; Santini Pereira BA; Cysne-Finkelstein L; Lechuga GC; Bourguignon SC; Almeida-Souza F; da Silva Calabrese K; Ferreira VF; Alves CR
Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():101-108. PubMed ID: 31430693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
